B

BioMark Diagnostics Inc
CNSX:BUX

Watchlist Manager
BioMark Diagnostics Inc
CNSX:BUX
Watchlist
Price: 0.48 CAD -4% Market Closed
Market Cap: CA$50.4m

Operating Margin

-1 231.3%
Current
Improving
by 0.8%
vs 3-y average of -1 232.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 231.3%
=
Operating Income
CA$-1.9m
/
Revenue
CA$154.9k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 231.3%
=
Operating Income
CA$-1.9m
/
Revenue
CA$154.9k

Peer Comparison

Country Company Market Cap Operating
Margin
CA
BioMark Diagnostics Inc
CNSX:BUX
50.4m CAD
Loading...
US
Natera Inc
NASDAQ:NTRA
31.5B USD
Loading...
US
Exact Sciences Corp
NASDAQ:EXAS
19.4B USD
Loading...
FR
Biomerieux SA
PAR:BIM
11.5B EUR
Loading...
US
Guardant Health Inc
NASDAQ:GH
13.6B USD
Loading...
US
Caris Life Sciences Inc
NASDAQ:CAI
7.2B USD
Loading...
KR
HLB Inc
KOSDAQ:028300
8.8T KRW
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
42.8B CNY
Loading...
CH
Siegfried Holding AG
SIX:SFZN
4.3B CHF
Loading...
IT
DiaSorin SpA
MIL:DIA
3.9B EUR
Loading...
UK
Abcam PLC
LSE:ABC
2.8B GBP
Loading...

Market Distribution

Lower than 90% of companies in Canada
Percentile
10th
Based on 4 855 companies
10th percentile
-1 231.3%
Low
-4 710 029.9% — -65.8%
Typical Range
-65.8% — 11%
High
11% — 71 100%
Distribution Statistics
Canada
Min -4 710 029.9%
30th Percentile -65.8%
Median -2.4%
70th Percentile 11%
Max 71 100%

BioMark Diagnostics Inc
Glance View

Market Cap
50.4m CAD
Industry
N/A

BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-11-03. The Company’s cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The firm is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The firm has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.

BUX Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 231.3%
=
Operating Income
CA$-1.9m
/
Revenue
CA$154.9k
What is BioMark Diagnostics Inc's current Operating Margin?

The current Operating Margin for BioMark Diagnostics Inc is -1 231.3%, which is above its 3-year median of -1 232.1%.

How has Operating Margin changed over time?

Over the last 3 years, BioMark Diagnostics Inc’s Operating Margin has increased from -2 031% to -1 231.3%. During this period, it reached a low of -2 031% on Jun 30, 2022 and a high of -988.5% on Mar 31, 2024.

Back to Top